health
February 11, 2026
Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs
Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.
TL;DR
- Novo Nordisk CEO Mike Doustdar expects to target approximately 15 million Medicare patients when obesity treatments are covered starting this year.
- Medicare coverage is expected to broaden the market and encourage private insurers to cover obesity medicines.
- Doustdar anticipates a gradual increase in prescription volumes due to Medicare coverage and the launch of Novo's new obesity pill.
- Novo is focusing on the effectiveness of its Wegovy obesity pill, claiming it is more effective than Lilly's oral drug.
- A higher dose of Wegovy is set to launch, aiming to match the efficacy of Lilly's Zepbound and attract more patients.
Continue reading the original article